AlzeCure Pharma: New preclinical data strengthens ACD856 - Redeye
Bildkälla: Stockfoto

AlzeCure Pharma: New preclinical data strengthens ACD856 - Redeye

Redeye comments on AlzeCure Pharma presenting new preclinical data for NeuroRestore ACD856 at the AD/PD Conference in Copenhagen (17–21 March 2026). The presentation provides deeper mechanistic validation and reinforces the asset’s potential in multiple CNS indications.

Redeye comments on AlzeCure Pharma presenting new preclinical data for NeuroRestore ACD856 at the AD/PD Conference in Copenhagen (17–21 March 2026). The presentation provides deeper mechanistic validation and reinforces the asset’s potential in multiple CNS indications.
Börsvärldens nyhetsbrev